Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $639,296.40 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 14,334 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the sale, the chief executive officer now owns 589,552 shares in the company, valued at $26,294,019.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Twist Bioscience Stock Performance

Shares of TWST opened at $45.40 on Friday. The stock has a market capitalization of $2.66 billion, a PE ratio of -11.88 and a beta of 1.78. The company has a 50 day moving average price of $43.69 and a 200-day moving average price of $45.54. Twist Bioscience Co. has a fifty-two week low of $15.85 and a fifty-two week high of $60.90.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TWST. Robert W. Baird increased their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Barclays cut their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $51.22.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. Signaturefd LLC raised its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. raised its stake in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience in the second quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.